Respiratory Syncytial Virus (RSV) Epidemiology

DelveInsight’s ‘Respiratory syncytial virus (RSV) Overview - Epidemiology Forecast–2034’ report delivers an in-depth understanding of the Respiratory syncytial virus (RSV) historical and forecasted epidemiology as well as the Respiratory syncytial virus (RSV) epidemiology trends in the United States.

Geographies Covered

• The United States

Study Period: 2021-2034

Respiratory syncytial virus (RSV) Understanding

Respiratory syncytial virus (RSV) Overview

RSV is a non-segmented virus with negative sense single-stranded RNA genome encoding 11 proteins. Out of those, two surface transmembrane proteins, G and F, have been shown to play a key role in RSV binding and fusion, respectively. The virus is classified into two subtypes: A and B, with about 50% genetic diversity in the G gene and 10% differences in the F gene. Due to less antigenic variability of the F protein compared with the G protein, this protein is the main target of research for developing antivirals as well as anti-RSV vaccines.

 

Respiratory Syncytial Virus (RSV) is a common virus that infects children and adults; however, children younger than two years of age tend to develop more serious respiratory symptoms. Although respiratory syncytial virus (RSV) disease is self-limiting in otherwise healthy children and adults, serious lower respiratory tract infections (LRTI) such as bronchiolitis and pneumonia requiring hospitalization can occur in infants, high-risk children, adults with comorbidities, and elderly adults.

Continued in the report…

 

Pathophysiology

RSV is the most common agent to cause lower respiratory tract infections (LRTI) among children below 5 years. Most of those acquire mild to moderate disease manifestations, and about 2–3% progress to severe illness resulting in hospitalization. Factors contributing to RSV pathogenesis and disease severity could be a viral, host, and environmental factors.

 

Diagnosis

RSV is one of the most common agents of upper and lower respiratory illnesses in infants and children worldwide. Infected individuals may present with mild, cold-like symptoms that are clinically indistinguishable from other viral respiratory infections. RSV typically occurs during the late fall, winter, and spring months and is generally self-limiting.

 

However, RSV can also manifest as severe infections, such as bronchiolitis and pneumonia, and is a significant cause of morbidity and mortality in young children, older adults, and immunocompromised patients.

 

RSV is usually diagnosed based on clinical presentation and patient history; however, the following populations warrant laboratory testing during RSV season if they present with severe respiratory illness:

• Young children (especially infants younger than 6 months)
• Adults 65 years or older
• Those with underlying heart and lung diseases (e.g., congestive heart failure, chronic obstructive pulmonary disease)

 

Treatment and Management

 

Supportive care

Supportive care is the mainstay of treatment for RSV bronchiolitis. Most infants can be managed at home, but those who are ill-appearing, dehydrated, have poor feeding, apnea, develop respiratory distress or require supplemental oxygen should be considered for hospitalization. The typical length of stay in the hospital ranges 3–7 days.

 

Supportive care includes hydration (i.e., oral or intravenous), clearing nasal obstruction with saline nose drops, nasal bulb suction or deep suctioning in the hospital, and nutrition for the patient. Oral feedings should be encouraged. Temporary feeding tubes (e.g., nasogastric) may be required in rare situations. Oxygen may be needed in those struggling to keep their oxygen saturation >90%, and it is recommended for patients whose saturations are consistently <90%. Mechanical ventilation is considered in those with respiratory failure and/or severe apnea.

Continued in the report…..

Respiratory syncytial virus (RSV) Epidemiology  

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Respiratory syncytial virus (RSV) in the United States, Type-specific Incident Cases of Respiratory syncytial virus (RSV) in the United States in between 2021 to 2034.

 

Key Findings

• In 2021, the total cases of Respiratory syncytial virus (RSV) in the US were 4,879,725, and these cases are anticipated to increase during the study period.
• In terms of type-specific Incident cases of RSV, the cases of RSV-Type A are more in comparison to RSV- Type B across the US in case of children.
• In adults, RSV-Type B cases were found slightly higher than RSV-Type A cases, in the US.
• Total incident cases of RSV were found highest in below 5 years, followed by 65 years and above, and the least number of cases were found in 5 to 64 years age group.

Scope of the Report

• The report covers a descriptive overview of Respiratory syncytial virus (RSV), explaining its procedure, types, indications, and currently available therapies.
• The report provides insight into the US historical and forecasted patient pool covering the United States.
• The report assesses the Respiratory syncytial virus (RSV) risk and burden.
• The report provides the segmentation of the epidemiology for the US by segmented by Total Incident Cases of Respiratory syncytial virus (RSV) in the United States, Type-specific Incident Cases of Respiratory syncytial virus (RSV) in the United States in between 2021 to 2034.

Report Highlights

• 10-year forecast of Respiratory syncytial virus (RSV)
• The US Coverage
• Total Incident Cases of Respiratory syncytial virus (RSV) in the United States
• Type-specific Incident Cases of Respiratory syncytial virus (RSV) in the United States

Key Questions Answered

• What are the risk, burdens, and unmet needs of Respiratory syncytial virus (RSV)?
• What is the historical Respiratory syncytial virus (RSV) patient pool in the United States?
• What would be the forecasted patient pool of Respiratory syncytial virus (RSV) at the US level?
• What will be the growth opportunities across the US with respect to the patient population pertaining to Respiratory syncytial virus (RSV)?
• At what CAGR the population is expected to grow across the US during the forecast period (2025-2034)?

Reasons to buy

The Respiratory syncytial virus (RSV) report will allow the user to -

• Develop business strategies by understanding the trends, shaping and driving the US Respiratory syncytial virus (RSV) epidemiology.
• The Respiratory syncytial virus (RSV) epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The Respiratory syncytial virus (RSV) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.